relapsed or refractory non-Hodgkin lymphoma | Drugs Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

136,518 results for “relapsed or refractory non-Hodgkin lymphoma”

bispecific CD19/CD22 CAR T-cell therapy ( relapsed/refractory B-cell Non-Hodgkin Lymphoma)

anti-CD22 degrader-antibody conjugates (non-Hodgkin lymphoma/NSCLC)

anti-BCMA CAR T-cell therapy (refractory or relapsed multiple myeloma)

anti-TriPRIL CAR T-cell therapy (relapsed or refractory multiple myeloma)

Pixantrone(Pixuvri)

Conditions: Non-Hodgkin's Lymphoma, Relapsed, Refractory Non-Hodgkin's lymphoma

C₁₇H₁₉N₅O₂

Anti-CD20 + anti-CD30 CAR T-cell therapy (relapsed/refractory lymphoma)

Investigational

Odronextamab(Ordspono)

anti-CD19 CAR T-cell therapy (B-cell non-Hodgkin lymphoma)

Non-Hodgkin's lymphoma vaccine(CellGenix GmbH)

Non-Hodgkin's lymphoma vaccine (XEME Biopharma)

Page 1 of 174